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,Peripheral artery disease (PAD) is a manifestation of
systemic atherosclerosis and part of the cardiovascular
(CV) disease continuum. Global prevalence increased by
nearly 25% from 2000 to 2010 and is estimated to affect
N200 million subjects worldwide [1]. Patients with PAD
have elevated levels of platelet activity and are at
substantial increased risk for platelet-mediated adverse
CV events, such as myocardial infarction (MI), ischemic
stroke, and CV death [2]. Clinical manifestations associ-
ated with lower extremity PAD include decrements in
functional capacity and quality of life, including loss of
limb in severely affected patients.
Current treatment guidelines recommend antiplatelet
therapy to reduce the risk of MI, stroke, or vascular death
in patients with PAD [3–5] and specifically recommend
monotherapy with a daily dose of aspirin 75-325 mg or
clopidogrel 75 mg as safe and effective antiplatelet
therapy. However, a meta-analysis of aspirin versus
placebo or control in 18 prospective randomized trials
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Volume 175comprising 5,269 subjects with PAD demonstrated no
statistically significant reduction in CV events with aspirin
therapy [6]. More recent studies of aspirin in subjects
with asymptomatic PAD or PAD with diabetes also failed
to show a benefit of aspirin [5,7–9].
Clopidogrel in PAD
Clopidogrel, an irreversible P2Y12 receptor antagonist,
75 mg daily is recommended as an alternative antiplatelet
therapy to aspirin in individuals with PAD. The Clopido-
grel versus Aspirin in Patients at Risk of Ischaemic Events
study demonstrated significant but modest benefit of
clopidogrel monotherapy over aspirin monotherapy in
patients with recent MI, stroke, or symptomatic PAD over
the 36-month study duration [10]. The beneficial effect
was mainly driven by the 24% relative risk reduction seen
in the composite end point in the PAD subgroup (P for
interaction b .05). Dual antiplatelet therapy has not been
shown to significantly decrease CV events in the setting
of stable PAD [11]. Accordingly, the European Society of
Cardiology, Inter-Society Consensus for the Management
of Peripheral Arterial Disease, American College of
Cardiology Foundation/American Heart Association, and
American College of Chest Physicians guidelines do not
recommend routine dual antiplatelet therapy in PAD on
the basis of there being no additional benefit and an
increased bleeding risk [3–5,12].
Ticagrelor
Ticagrelor is a reversibly binding, potent, oral adenosine
diphosphate P2Y12 receptor blocker. The Study of Platelet
Inhibition and Patient Outcomes (PLATO) [13] trial
demonstrated superiority of ticagrelor over clopidogrel in
the prevention of fatal and nonfatal CV events in patients
with acute coronary syndrome on background aspirin
therapy. The primary safety end point, PLATO-defined
“major bleeding,” did not differ significantly from clopido-
grel. In the subgroup of patients with PAD in the PLATO
trial, the reduction in ischemic events with ticagrelor
versus clopidogrel was consistent with the overall trial
results [14].
The Prevention of Cardiovascular Events in Patients with
Prior Heart Attack Using Ticagrelor Compared to Placebo
on a Background of Aspirin–Thrombolysis in Myocardial
Infarction (PEGASUS-TIMI 54) 54 trial randomized 21,162
patients with prior MI 1 to 3 years earlier to ticagrelor 90
mg, 60 mg, or placebo twice daily on a background of
low-dose aspirin for amedian of 33months. Both ticagrelor
doses reduced the primary composite end point of CV
death, MI, or stroke as compared with placebo. Rates of
TIMI major bleeding were higher with both ticagrelor
doses, with no difference in the rates of intracranial
hemorrhage or fatal bleeding among the 3 groups [15].
The Effects of Ticagrelor and Clopidogrel in Patients
with Peripheral Artery Disease (EUCLID) study is beingconducted to determine whether treatment with tica-
grelor, given as antiplatelet monotherapy, compared with
clopidogrel monotherapy will reduce the incidence of
atherothrombotic ischemic events as measured by the
composite end point of CV death, MI, or ischemic stroke
in a population with established PAD.
Study design and population
EUCLID is an international, multicenter, randomized,
double-blind, parallel-group, end point–driven phase IIIb
study to assess the prevention of atherothrombotic
events with ticagrelor 90 mg twice daily compared with
clopidogrel 75 mg daily in patients with established PAD.
The study design is shown in Figure (ClinicalTrials.gov
no., NCT01732822) [16].
The inclusion criteria for EUCLID are designed to enroll
a representative sample of subjects with PAD. Study
patients must be ≥50 years of age with symptomatic
PAD, defined by 1 of the following: (1) ankle-brachial
index (ABI) ≤0.80 and lower extremity symptoms, or (2)
prior lower extremity revascularization (Table I).
For patients qualifying via the ABI criteria, 2 distinct
measurements are required—at entry, the ABI measure-
ment must be ≤0.80; and at the subsequent randomiza-
tion visit,≤0.85. This is done to improve the specificity of
the ABI to ensure that patients enrolled have substantial
hemodynamic evidence of PAD (given the 0.10 test-retest
variation, an ABI of 0.80 ensures that the upper bound
would be ≤0.90) [17,18]. If ABI is ≥1.40, a toe-brachial
index (TBI) ≤0.60 at visit 1 and ≤0.65 at visit 2 is
alternatively accepted. Patients with prior lower extrem-
ity revascularization for symptomatic PAD qualify for
enrollment if revascularization was N30 days before
randomization, irrespective of present leg symptoms
and hemodynamics at the time of study screening.
Key exclusion criteria include planned use of dual
antiplatelet therapy, requirement of aspirin, history of
bleeding diathesis, treatment with anticoagulation, or
poor metabolizer status for CYP2C19, defined as
possessing a genotype consisting of 2 loss-of-function
alleles. All patients must provide written informed
consent for participation. A complete listing of the
inclusion/exclusion criteria is provided in Table I.
EUCLID patients were being randomized in a 1:1 ratio
to receive either ticagrelor monotherapy or clopidogrel
monotherapy. Recruitment began in December 2012 and
was completed in March 2014, and 13,887 patients were
randomized. Two patients were determined to be double
enrolled and randomized (ie, same patient enrolled and
randomized at 2 separate sites); therefore, the total
number of randomized subjects was 13,885. The baseline
characteristics of patients enrolled in EUCLID are shown
in Table II. Randomized patients are being followed for all
clinical end points and serious adverse events (AEs) until
the end of the study, with the primary and several
Figure
EUCLID Study Design
Patients with symptomatic PAD
Primary endpoint: cardiovascular death, myocardial infarction, or ischemic stroke
Double-blind
Double-dummy
1:1
N ~ 13,500
ClinicalTrials.gov Identifier: NCT01732822
Ticagrelor
90 mg bid
Clopidogrel
75 mg od
Follow-up visits 2, 6, 12 months;
Every 6 months after 1st year
Telephone visits at 3-month intervals between regular visits
EUCLID study design.
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adjudication. The trial will continue until at least 1,364
adjudicated primary end points (CV death, MI, or
ischemic stroke) have accrued.
The study is being performed in accordance with ethical
principles consistent with the Declaration of Helsinki,
International Conference on Harmonisation Good Clinical
Practice guidelines, and applicable regulatory requirements.
The final study protocol and informed consent have been
reviewed and approved by the corresponding health
authorities and ethics boards/institutional review boards
for all participating study sites. Enrolled patients gavewritten
informed consent for participation in the trial.
Treatment protocol and follow-up
procedures
Treatment selection and compliance
Study drug is administered as either double-blind
ticagrelor 90 mg twice daily or clopidogrel 75 mg once
daily (ticagrelor or matching placebo versus clopidogrel
or matching placebo in the morning and ticagrelor or
matching placebo in the evening). The ticagrelor 90-mg
dose was well tolerated and showed high and consistentlevels of platelet inhibition in phase II studies, with an
acceptable safety profile [19,20]. Moreover, PLATO
showed a positive clinical benefit-risk balance with this
dose [13]. The clopidogrel 75-mg daily dose was selected
because it is the approved maintenance dose in clinical
practice. No loading dose is administered because a rapid
onset is not required in the stable setting. During the
study, it is anticipated that some patients may develop an
indication for a loading dose of P2Y12 receptor antago-
nist. A modified study treatment option is provided to
investigators to allow an additional 90 mg of ticagrelor or
placebo and up to 600 mg of clopidogrel or placebo as a
supplemental loading dose.
Concomitant therapies
All patients in EUCLID are recommended to be on
standard CV prevention therapies, including statins, consis-
tent with recommendations for subjects with established
PAD. Additional antithrombotic therapy was prohibited
including other P2Y12 receptor antagonists, long-term
anticoagulants at therapeutic doses, and other platelet
inhibitors. Dual antiplatelet therapy at the start of the study
was prohibited but allowed if a clinical indication (eg, MI)
occurred during the course of follow-up with the allowance
Table I. Inclusion and exclusion criteria
Inclusion
At least 50 y of age
Symptomatic PAD defined by:
A. PAD symptoms plus ABI criteria
-PAD symptoms consist of classic claudication, other exertional leg
discomfort associated with physical limitations from PAD, ischemic rest
pain, ischemic ulcers, or gangrene
-ABI ≤0.80 at V1 and ≤0.85 at V2
-If ABI is ≥1.40, then the TBI must be ≤0.60 at V1 and ≤0.65 at V2
OR
B. Prior lower extremity revascularization for symptomatic PAD>30daysago
Written informed consent before any study specific procedures
Exclusion
Poor metabolizer status for CYP2C19, defined as possessing genotype
consisting of 2 loss-of-function alleles
Hypersensitivity to clopidogrel or ticagrelor
Patients requiring dual antiplatelet therapy at study entry
Need for long-term oral anticoagulant therapy or long-term
low-molecular-weight heparin or long-term treatment with fondaparinux
Planned (and judged necessary) use of ticlopidine, prasugrel,
aspirin, or dipyridamole
Planned (and judged necessary) use of omeprazole or esomeprazole.
The use of other proton pump inhibitors is permitted.
Any condition which in the opinion of the investigator would make it
unsafe or unsuitable for the patient to participate in this study
(eg, active malignancy other than squamous cell or basal cell skin
cancer, use of strong or moderate CYP2C19 inhibitors, long-term
concomitant treatment with nonsteroidal anti-inflammatory drugs)
Life expectancy b6 m based on investigator’s judgment
Planned revascularization (surgical or endovascular) in any vascular
territory within the next 3 m
Planned major amputation due to PAD within the next 3 m or major
amputation due to PAD within the last 30 d
Patients who have suffered a stroke during the past 3 m
Dementia likely to jeopardize understanding of information pertinent to
study conduct or compliance to study procedures
Severe hypertension that may put the patient at risk
Patients considered to be at risk of bradycardic events (eg, known sick sinus
syndrome or second- or third-degree atrioventricular block) unless already
treated with a permanent pacemaker
Known severe liver disease (eg, ascites and/or clinical signs of coagulopathy)
Renal failure requiring dialysis
A clinically important bleeding diathesis, hemostatic or coagulation
disorder, or systemic bleeding
History of previous intracranial bleed at any time, gastrointestinal bleed
within the past 6 m, or major surgery within 30 d (if the surgical wound is
judged to be associated with an increased risk of bleeding)
Clinically important thrombocytopenia or neutropenia
Women of child-bearing potential (ie, those who are not chemically or
surgically sterilized or who are not postmenopause) who are not willing
to use a medically accepted method of contraception that is considered
reliable in the judgment of the investigator OR women who have
a positive pregnancy test result at visit 1
Concern for inability of the patient to comply with study procedures
and/or follow-up (eg, alcohol or drug abuse)
Previous randomization in the present study
Involvement in the planning and/or conduct of the study (applies to both
AstraZeneca staff and staff at the study center)
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Volume 175for the addition of open-label aspirin. Planned concomitant
treatment with any approved phosphodiesterase D3 inhib-
itor for claudication (cilostazol, pentoxifylline, or naftidro-furyl) is permitted. Additional details are described in online
Appendix A.
Recommendations for patients undergoing procedures
For elective cardiac and major noncardiac surgery
which in the opinion of the investigator poses a risk for
clinically major bleeding, patients are advised to stop
study treatment 5 days before the procedure and resume
when determined appropriate by the treating physician.
For other surgery or invasive procedures, study medica-
tion may be continued or interrupted temporarily at the
discretion of the investigator. It is also recommended that
study medication not be discontinued for significantly
longer than 5 days to minimize the risk of thrombotic
complications while off study medication.
Visit schedule and follow-up
Randomized patients return for study visits at months 2,
6, and 12 during the first year followed by in-person
6-month visits thereafter until the end of the trial, to be
determined when the projected number of at least 1,364
primary efficacy end points is about to be reached. There is
a telephone visit every 6months beginning atmonth 9 until
the end of the trial. During follow-up visits, patients are
assessed for adverse and potential end point events. All
patients are to undergo an End of Treatment visit when
permanently stopping therapy and a follow-up contact
approximately 2weeks after their last dose of study drug. It
is recommended that all randomized patients attend the
final study visit in person regardless of whether or not they
are taking randomized study treatment. Vital status will be
assessed in all patients at the end of the trial.
ABI and TBI measurements
The ABI/TBI was measured at visit 1 in all subjects and at
both visits 1 and 2 in those enrolled under the ABI/TBI
criteria; subsequent ABI/TBI measurements were obtained
at the 6-month visit and at the end of the study visit. The
measurement ankle vessel and limb used at the first 2 visits
were identified and used for all subsequent visits. The first 2
ABI measurements for the first 3 subjects at each site were
assessed for quality by the ABI core laboratory (see below).
The ABI/TBI was used to determine eligibility for the
study for patients enrolling under ABI criteria. The ABI/
TBI will also serve as an exploratory end point in the trial
to address the progression of disease over time and to test
the hypothesis that ticagrelor reduces the rate of decline
in ABI/TBI relative to clopidogrel.
The ABI core laboratory was formed to provide a
quality control check on the measurement to ensure that
patients meet the ABI inclusion criterion and to avoid
misclassification, which could adversely affect the
proposed event rate. The ABI core laboratory performed
regular data monitoring on ABI/TBI reproducibility at
entry and any outliers by site, country, and region. Based
Table II. Baseline characteristics of patients included in EUCLID
at study entry (not final data [data as of November 30, 2015])⁎
All patients
(N = 13885)†
Age, median (25th, 75th), y 66.0 (60.0, 73.0)
Male sex 9997 (72.0)
Inclusion criteria for randomization
Prior revascularization 7878 (56.7)
ABI/TBI criterion 6007 (43.3)
ABI findings at randomization,
median (25th, 75th)‡
0.70 (0.58, 0.82)
Medical history
History of stroke 1134 (8.2)
History of TIA 506 (3.6)
MI 2518 (18.1)
Prior PCI or CABG 3218 (23.2)
Diabetes mellitus 5342 (38.5)
Hypertension requiring drug therapy 10839 (78.1)
Hyperlipidemia requiring drug therapy 10462 (75.4)
Tobacco use
Never smoked 2990 (21.7)
Current smoker 4285 (31.0)
Former smoker 6527 (47.3)
Data presented as number (percentage), unless otherwise indicated. TIA, Transient
ischemic attack; PCI, percutaneous coronary intervention; CABG, coronary artery
bypass grafting surgery.
⁎A patient may meet more than 1 exclusion criteria.
†N represents total number of patients, not randomizations. Two patients were
determined to be double enrolled (ie, same patient enrolled at 2 separate sites);
therefore, the total number of randomized subjects was 13,885.
‡ABI (or TBI) is calculated from site-reported measurements in the CRF and is
calculated as the average of enrollment and randomization ABI (or TBI) measure-
ments, where, at each visit, the highest of the right and left ABIs (or TBIs) is selected.
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interventions to address excess variability were incre-
mental, starting with site feedback by e-mail and
newsletters and extending to site visits to observe the
conduct of the ABI/TBI with site personnel and provide
retraining as needed.
Study end points
The primary end point in the trial is the composite of
CV death, MI, or ischemic stroke. The major secondary
end point is the composite of CV death, MI, ischemic
stroke, and acute limb ischemia (ALI) requiring hospital-
ization. ALI was chosen as an end point because of
significant limb morbidity observed in subjects with PAD.
In addition, antiplatelet therapy with a protease-activated
receptor–1 antagonist demonstrated a reduction in major
adverse limb events [21]. Definitions of study end points
are detailed in online Appendix B.
The primary safety objective of this study is major
bleeding using the TIMI definition. Bleeding events will
also be adjudicated using the PLATO, Bleeding Academic
Research Consortium, and International Society on
Thrombosis and Haemostasis definitions. Safety will be
assessed through standard ascertainment of site-reportedAEs. Non-serious AEs of interest (ie, bleeding events,
dyspnea, renal impairment/increased creatinine, bradyar-
rhythmia, increased liver function tests, gout/uric acid
increases, pneumonia, gynecomastia, abnormal uterine
bleeding, all malignancies excluding nonmelanoma skin
cancers), AE events that are ongoing at the time of
permanent discontinuation of study medication due to an
AE, and all serious AEs will be reviewed within the
context of the earlier safety experience with the drug.
All efficacy and bleeding safety end points are
site-reported in an electronic Web-based capture system
with submission of supporting source documentation
where applicable. Adjudication for each event is per-
formed according to definitions in the EUCLID Clinical
End Points Committee Charter (online Appendix B) by an
independent, blinded, and trained clinical end points
committee with board certification in either cardiology
or neurology, depending on the event type.Statistical considerations
The primary efficacy variable is time from randomiza-
tion to first occurrence of any event from the primary
composite of CV death, MI, or ischemic stroke. The
primary variable will be tested at 4.94% significance level
(2-sided) to account for 1 planned interim analysis with
the overall type I error maintained at 5%. The analysis of
all efficacy variables will be based on the intention-to-treat
principle using the Cox proportional hazards model with
a factor for treatment group. The hazard ratio for
ticagrelor versus clopidogrel with 95% CIs will be
presented. To address the issue of multiple testing, the
confirmatory analysis will comprise a hierarchical test
sequence with the primary efficacy variable followed by
the secondary efficacy variables in the order listed in
Table III. The confirmatory testing will continue at the
4.94% significance level until the first statistically
nonsignificant difference of treatment effect in the
sequence is observed. Efficacy analyses will be conducted
on an intention-to-treat basis among all subjects random-
ized. The safety evaluation will include all subjects who
receive at least 1 dose of study treatment and within 7
days of last study drug dose. Subgroup analyses will be
performed to evaluate variation of treatment effect, as
well as a test of interaction with treatment for each
subgroup variable. The P values of the subgroup analyses
and interaction tests will not be adjusted for multiple
comparisons because the tests are exploratory and will be
interpreted descriptively. Subgroup analyses will be
performed on the primary efficacy and safety variables.
Subgroup analyses will be based on the set of baseline
variables (online Appendix Supplementary Table I).
Trial sample size estimation required estimates of event
rates in subjects with symptomatic PAD. Estimates were
made using the best available data. PAD subgroups
were analyzed from prior trials [10,22,23] and registries
Table III. Secondary end points
1. Composite of CV death, MI, ischemic stroke, or
hospitalization for ALI
2. CV death
3. MI
4. All-cause mortality
5. The composite of CV death, MI, or all-cause stroke
(ischemic or hemorrhagic)
6. Hospitalization for ALI
7. Lower extremity revascularization
8. Composite of all revascularizations (coronary and
peripheral [limb, mesenteric, renal, carotid, and other])
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the proportion of subjects estimated to be enrolled with
different ABI cutoffs, prevalence of polyvascular disease,
and critical limb ischemia. Data from the PAD subgroup
in PLATO demonstrated a similar 15% relative risk
reduction as the overall trial results with a greater
absolute risk reduction [14].
To detect a true hazard ratio of 0.85, randomization of
approximately 11,500 patients was expected to yield 1,596
primary end point events, providing 90% power at 4.94%
significance level. The initial sample size was calculated
basedon the assumptionof a 6%-6.5%per year aggregate rate
of CV death, MI, or ischemic stroke. Because of the
lower-than-expected event rate, the EUCLID Executive
Committee modified the trial to preserve adequate power
to test the primary study hypothesis. The protocol was
amended inDecember 2013 to increase the sample size from
11,500 to at least 13,500 randomized patients. In March
2015, the targeted number of primary events was reduced
from 1,596 to a minimum of 1,364, resulting in a decrease in
power from 90% to 85% at 4.94% significance level.
An independent data monitoring committee (DMC)
has responsibility for monitoring safety during the trial
and will perform at least 1 interim analysis of efficacy
when approximately half of the projected primary end
points have been accrued and adjudicated. At its
discretion, the independent DMC may perform addition-
al efficacy looks. An alpha spending function will govern
interim and final statistical testing to control the overall
type I error of 5%.
Platelet substudy
A platelet substudy, conducted in the United States, will
assess pharmacodynamics as measured through platelet
function testing. The platelet substudy is being per-
formed in 10 centers comparing the effects of the study
treatments on adenosine diphosphate–induced platelet
light transmission aggregation, vasodilator-stimulated
phosphoprotein enzyme-linked immunosorbent assay–
based assay (BioCytex, Marseille, France), and VerifyNow
P2Y12 assay (Accumetrics, San Diego, CA).Study organization
The EUCLID trial is being conducted in 28 countries
and 821 sites. The trial operations group is a partnership
composed of members of the Duke Clinical Research
Institute (DCRI; Durham, NC), Colorado Prevention
Center (Denver, CO), and AstraZeneca (London, UK),
the trial sponsor (online Appendix C). An executive
committee monitors ongoing conduct of the trial. An
international steering committee composed of academic
experts and national lead investigators for each country is
responsible for the protocol and its implementation. An
independent DMC is responsible for period reviews of
patient safety during the trial.
EUCLID was designed by the executive committee in
cooperation with DCRI and the trial sponsor. Indepen-
dent data analyses will be conducted by DCRI with
validation by the trial sponsor. The executive committee
has free and complete access to all trial data and will
submit the results of the study for publication in a
peer-reviewed medical journal.
The EUCLID study is supported by a research grant
from AstraZeneca. The authors are solely responsible for
the design and conduct of this study, all study analyses,
the drafting and editing of the manuscript, and its final
contents.Discussion
Despite the increasing number of patients with lower
extremity PAD [1], the evidence base for therapies aimed
at improving both CV and limb outcomes is limited [29].
The current American College of Cardiology Foundation/
American Heart Association/European Society of Cardi-
ology guidelines for PAD recommend use of either
aspirin or clopidogrel for reduction in CV events [4,5].
Unfortunately, these recommendations are based on the
evaluation of effects in patients with PAD that were
subgroups in larger trials. The EUCLID trial will define
the role of antiplatelet therapy in patients with symp-
tomatic PAD.
Therefore, as we considered a large trial aimed at
patients with PAD, there were several important design
considerations, including the population to be enrolled,
the comparative therapies, management of patients
during the trial, and the outcomes of interest.
Study population
Symptomatic patients with PAD are at high risk of CV
events and require aggressive lifestyle and pharmacologic
therapy for risk reduction. To address the paucity of data
in PAD, the EUCLID trial includes the entire spectrum of
symptomatic PAD, including abnormal ABI (ABI b0.80) or
TBI (b0.60 with ABI N1.4), typical and atypical lower
extremity symptoms, and rest pain with critical limb
ischemia. In addition, EUCLID was designed to include
92 Berger et al
American Heart Journal
May 2016patients with or without revascularization (endovascular
or surgical) or amputation.
Comparative antiplatelet therapy
When designing the study, different antiplatelet compar-
ative groups were considered, including aspirin monother-
apy, clopidogrelmonotherapy, or dual antiplatelet therapy.
The benefit of aspirin in the setting of PAD is far from
certain. A meta-analysis including 9 trials of subjects with
PAD did not detect a significant difference in CV events
from aspirin versus placebo or control [6]. Clopidogrel
monotherapy outperformed aspirin monotherapy in pa-
tients with prior MI, stroke, or PAD. In fact, the largest
reduction in CV events from clopidogrel was observed in
the PAD cohort, suggesting a greater effect of clopidogrel
in the setting of PAD [10]. The CHARISMA trial failed to
demonstrate a significant benefit of dual antiplatelet
therapy in the overall trial [22] or in the PAD cohort [11].
Overall, this suggested that clopidogrel monotherapy was
the most proven antiplatelet therapy strategy in subjects
with PAD. To permit the most unbiased comparison of
clopidogrel to ticagrelor, patients with 2 loss-of-function
CYP2C19 alleles are excluded from the EUCLID trial.
Management during the study
EUCLID is designed as a pragmatic clinical trial. As
such, usual or standard care is permitted, including
endovascular or surgical interventions for treatment of
symptomatic PAD. Although aspirin use is an exclusion
criterion at the onset of the trial, the addition of aspirin is
permitted in certain subjects (eg, incident CV event or
revascularization) where dual antiplatelet therapy is
recommended. For patients undergoing procedures,
continuation of therapy was recommended, and a
physician-supported helpline was available 24 hours a
day, 7 days a week to answer clinical questions.
Limb end points
Clinically important limb events are being investigated
and adjudicated as secondary end points of this trial.
Because the population being studied is patients with
symptomatic PAD, limb-specific end points are impor-
tant to understand for this high-risk population. For that
reason, this study is investigating ALI requiring hospi-
talization with the primary composite end point as the
first major secondary end point. Other limb events
being investigated include lower extremity revasculari-
zation, lower extremity clinical status (Rutherford and
Fontaine stage), change in ABI (or TBI), amputation, and
peripheral artery questionnaire. Moreover, the recently
reported TRA2°P-TIMI 50 study compared vorapaxar, an
oral antiplatelet agent targeting the protease-activated
receptor–1 by thrombin, versus placebo in patients with
prior MI, stroke, or PAD. Although vorapaxar did not
reduce the primary composite end point in patientswith PAD, it significantly reduced ALI and peripheral
revascularization [21]. These data support the hypoth-
esis that potent antiplatelet therapy will reduce limb-
specific events.
Summary
The EUCLID trial is investigating whether ticagrelor
monotherapy versus clopidogrel monotherapy reduces
major CV and limb-specific events in a broad represen-
tative population of patients with PAD.Acknowledgements
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